Furthermore, combining lomitapide treatment significantly enhances the efficacy of anti-PD-1 therapy in reducing the growth of tumors in CRC and melanoma; this establishes efficacious anticancer effects of lomitapide across multiple different cancer types in preclinical in vivo models. The gene discussed is PDCD1; the disease is colorectal carcinoma.